

## **BetaGlue® Announces ASCO Abstract Publication of the use of YntraDose® in an Advanced Large Animal Model of Pancreatic Cancer**

**Milan, May 27<sup>th</sup> 2025** – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®, announced today that an abstract was published by the American Society of Clinical Oncology (ASCO) entitled: *“Preclinical study of safety and efficacy in vivo of a yttrium-90 resin microspheres glue formulation in a large animal model of pancreatic cancer.”*

The abstract describes the use of YntraDose to treat orthotopic tumors in an advanced in vivo porcine model called ‘oncopig’. Five animals were treated and followed-up over 30days, the findings were:

1. No adverse events were reported throughout the study period;
2. YntraDose implantation and its associated radiotherapeutic payload were confined to the site of administration as demonstrated by radiological PET/CT assessment; and
3. At 30days visual necropsy assessment not only revealed evidence of tumor necrosis but also indicated tumor debulking.

Dr Colin Story, CEO, BetaGlue Therapeutics commented: “This study utilised a cutting edge advanced large animal model of pancreatic cancer where procedures were performed by world-renowned Interventional Radiologist and key opinion leader Professor Govindarajan Narayanan. BetaGlue is focused on bringing YntraDose to patients that present with Locally-Advanced Pancreatic Cancer which by definition is inoperable. We are very grateful to our collaborators Prof. Narayanan, Dr Geschwind and Ms Felicia Bealo for their contribution to this work.”

Professor Govindarajan Narayanan, Chief of Interventional Oncology for the Miami Cancer Institute and lead author of the abstract commented: “Locally-Advanced Pancreatic Cancer (LAPC) accounts for around 30% of all Pancreatic Cancers worldwide. This study provides preliminary evidence of the utility for YntraDose as a local treatment option for LAPC with the potential to down-stage patients and enabling surgical resection to take place.”

Link to the published abstract: [Here](#)

### **About BetaGlue Therapeutics S.p.A.**

BetaGlue Therapeutics S.p.A. is an Italian clinical-stage oncology company developing a novel radiotherapy platform technology for the localised and targeted treatment of unresectable solid tumours called YntraDose®. BetaGlue enjoys the support of a global Clinical Advisory Board, as well as of leading national and international advisers, in the development of its products. Visit our website, [www.betaglue.com](http://www.betaglue.com). Visit our LinkedIn page [here](#).